The DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index.
Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes
Open accessAbstract
Somatically acquired genetic abnormalities lead to the salient features that define myelodysplastic syndromes (MDS): clonal hematopoiesis, aberrant differentiation, peripheral cytopenias, and risk of progression to acute myeloid leukemia. Although specific karyotypic abnormalities have been linked to MDS for decades, more recent findings have demonstrated the importance of mutations within individual genes, focal alterations that are not apparent by standard cytogenetics, and aberrant epigenetic regulation of gene expression. The spectrum of genetic abnormalities in MDS implicates a wide range of molecular mechanisms in the pathogenesis of these disorders, including activation of tyrosine kinase signaling, genomic instability, impaired differentiation, altered ribosome function, and changes in the bone marrow microenvironment. Specific alterations present in individual patients with MDS may explain much of the heterogeneity in clinical phenotype associated with this disease and can predict prognosis and response to therapy. Elucidation of the full complement of genetic causes of MDS promises profound insight into the biology of the disease, improved classification and prognostic scoring schemes, and the potential for novel targeted therapies with molecular predictors of response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
ASXL1 Represses Retinoic Acid Receptor-mediated Transcription through Associating with HP1 and LSD1
Lee, S.-W., Cho, Y.-S., Na, J.-M., Park, U., Kang, M., Kim, E., & Um, S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.065862 · Cited by 93
RetractedIDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., Harris, N. L., Le Beau, M. M., Hellström-Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,424
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70003-8 · Cited by 2,663
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
Self-citationOkuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G., & Downing, J. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80986-1 · Cited by 1,856
Mutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776
Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
Schlenk, R. F., Döhner, K., Krauter, J., Fröhling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Späth, D., Morgan, M., Benner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074306 · Cited by 1,628
Morin, R. D., Johnson, N. A., Severson, T. M., Mungall, A. J., An, J., Goya, R., Paul, J. E., Boyle, M., Woolcock, B. W., Kuchenbauer, F., et al. (2010) · Nature Genetics · doi:10.1038/ng.518 · Cited by 1,521
Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion
List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061292 · Cited by 1,319
Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2
Ko, M., Huang, Y., Jankowska, A. M., Pape, U. J., Tahiliani, M., Bandukwala, H. S., An, J., Lamperti, E. D., Koh, K. P., Ganetzky, R., et al. (2010) · Nature · doi:10.1038/nature09586 · Cited by 1,213
Wang, Q., Stacy, T., Binder, M., Marin-Padilla, M., Sharpe, A. H., & Speck, N. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3444 · Cited by 1,178
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Ernst, T., Chase, A. J., Score, J., Hidalgo-Curtis, C. E., Bryant, C., Jones, A. V., Waghorn, K., Zoi, K., Ross, F. M., Reiter, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.621 · Cited by 1,139
Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia
Raaijmakers, M. H. G. P., Mukherjee, S., Guo, S., Zhang, S., Kobayashi, T., Schoonmaker, J. A., Ebert, B. L., Al-Shahrour, F., Hasserjian, R. P., Scadden, E. O., et al. (2010) · Nature · doi:10.1038/nature08851 · Cited by 1,115
Self-citationIdentification of RPS14 as a 5q- syndrome gene by RNA interference screen
Ebert, B. L., Pretz, J., Bosco, J., Chang, C. Y., Tamayo, P., Galili, N., Raza, A., Root, D. E., Attar, E., Ellis, S. R., et al. (2008) · Nature · doi:10.1038/nature06494 · Cited by 928
Self-citationRibosomopathies: human disorders of ribosome dysfunction
Narla, A., & Ebert, B. L. (2010) · Blood · doi:10.1182/blood-2009-10-178129 · Cited by 809
Self-citationPaschka, P., Schlenk, R. F., Gaidzik, V. I., Habdank, M., Krönke, J., Bullinger, L., Späth, D., Kayser, S., Zucknick, M., Götze, K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.3762 · Cited by 801
Haase, D., Germing, U., Schanz, J., Pfeilstöcker, M., Nösslinger, T., Hildebrandt, B., Kundgen, A., Lübbert, M., Kunzmann, R., Giagounidis, A. A. N., et al. (2007) · Blood · doi:10.1182/blood-2007-03-082404 · Cited by 794
Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes
Nikoloski, G., Langemeijer, S. M. C., Kuiper, R. P., Knops, R., Massop, M., Tönnissen, E. R. L. T. M., van der Heijden, A., Scheele, T. N., Vandenberghe, P., de Witte, T., et al. (2010) · Nature Genetics · doi:10.1038/ng.620 · Cited by 755
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
Abdel-Wahab, O., Mullally, A., Hedvat, C., Garcia-Manero, G., Patel, J., Wadleigh, M., Malinge, S., Yao, J., Kilpivaara, O., Bhat, R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-210039 · Cited by 727
Self-citationStein, S., Ott, M. G., Schultze-Strasser, S., Jauch, A., Burwinkel, B., Kinner, A., Schmidt, M., Krämer, A., Schwäble, J., Glimm, H., et al. (2010) · Nature Medicine · doi:10.1038/nm.2088 · Cited by 716
Acquired mutations in TET2 are common in myelodysplastic syndromes
Langemeijer, S. M. C., Kuiper, R. P., Berends, M., Knops, R., Aslanyan, M. G., Massop, M., Stevens-Linders, E., van Hoogen, P., van Kessel, A. G., Raymakers, R. A. P., et al. (2009) · Nature Genetics · doi:10.1038/ng.391 · Cited by 680
Wattel, E., Preudhomme, C., Hecquet, B., Vanrumbeke, M., Quesnel, B., Dervite, I., Morel, P., & Fenaux, P. (1994) · Blood · doi:10.1182/blood.v84.9.3148.3148 · Cited by 591
Identification of miR-145 and miR-146a as mediators of the 5q– syndrome phenotype
Starczynowski, D. T., Kuchenbauer, F., Argiropoulos, B., Sung, S., Morin, R., Muranyi, A., Hirst, M., Hogge, D., Marra, M., Wells, R. A., et al. (2010) · Nature Medicine · doi:10.1038/nm.2054 · Cited by 577
Gelsi‐Boyer, V., Trouplin, V., Adélaïde, J., Bonansea, J., Cervera, N., Carbuccia, N., Lagarde, A., Prebet, T., Nezri, M., Sainty, D., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07697.x · Cited by 564
Role of nucleophosmin in embryonic development and tumorigenesis
Grisendi, S., Bernardi, R., Rossi, M., Cheng, K., Khandker, L., Manova, K., & Pandolfi, P. P. (2005) · Nature · doi:10.1038/nature03915 · Cited by 561
G ENETICS OF M YELOID L EUKEMIAS
Kelly, L. M., & Gilliland, D. G. (2002) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.3.032802.115046 · Cited by 523
Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype
Growney, J. D., Shigematsu, H., Li, Z., Lee, B. H., Adelsperger, J., Rowan, R., Curley, D. P., Kutok, J. L., Akashi, K., Williams, I. R., et al. (2005) · Blood · doi:10.1182/blood-2004-08-3280 · Cited by 462
Distinct haematological disorder with deletion of long arm of No. 5 chromosome
VAN DEN BERGHE, H., CASSIMAN, J.-J., DAVID, G., FRYNS, J.-P., MICHAUX, J.-L., & SOKAL, G. (1974) · Nature · doi:10.1038/251437a0 · Cited by 442
Lorsbach, R. B., Moore, J., Mathew, S., Raimondi, S. C., Mukatira, S. T., & Downing, J. R. (2003) · Leukemia · doi:10.1038/sj.leu.2402834 · Cited by 416
Morishita, K., Parker, D. S., Mucenski, M. L., Jenkins, N. A., Copeland, N. G., & Ihle, J. N. (1988) · Cell · doi:10.1016/s0092-8674(88)91175-0 · Cited by 404
Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms
Sanada, M., Suzuki, T., Shih, L.-Y., Otsu, M., Kato, M., Yamazaki, S., Tamura, A., Honda, H., Sakata-Yanagimoto, M., Kumano, K., et al. (2009) · Nature · doi:10.1038/nature08240 · Cited by 402
Aberrant DNA methylation is a dominant mechanism in MDS progression to AML
Jiang, Y., Dunbar, A., Gondek, L. P., Mohan, S., Rataul, M., O'Keefe, C., Sekeres, M., Saunthararajah, Y., & Maciejewski, J. P. (2009) · Blood · doi:10.1182/blood-2008-06-163246 · Cited by 384
Barjesteh van Waalwijk van Doorn-Khosrovani, S. (2003) · Blood · doi:10.1182/blood-2002-05-1459 · Cited by 355
DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes
Shen, L., Kantarjian, H., Guo, Y., Lin, E., Shan, J., Huang, X., Berry, D., Ahmed, S., Zhu, W., Pierce, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4781 · Cited by 355
Tang, J.-L., Hou, H.-A., Chen, C.-Y., Liu, C.-Y., Chou, W.-C., Tseng, M.-H., Huang, C.-F., Lee, F.-Y., Liu, M.-C., Yao, M., et al. (2009) · Blood · doi:10.1182/blood-2009-05-223784 · Cited by 344
Bellamy, W. T., Richter, L., Sirjani, D., Roxas, C., Glinsmann-Gibson, B., Frutiger, Y., Grogan, T. M., & List, A. F. (2001) · Blood · doi:10.1182/blood.v97.5.1427 · Cited by 342
A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q– syndrome
Barlow, J. L., Drynan, L. F., Hewett, D. R., Holmes, L. R., Lorenzo-Abalde, S., Lane, A. L., Jolin, H. E., Pannell, R., Middleton, A. J., Wong, S. H., et al. (2010) · Nature Medicine · doi:10.1038/nm.2063 · Cited by 334
Mutations of ASXL1 gene in myeloproliferative neoplasms
Carbuccia, N., Murati, A., Trouplin, V, Brecqueville, M., Adélaïde, J., Rey, J., Vainchenker, W., Bernard, O. A., Chaffanet, M., Vey, N., et al. (2009) · Leukemia · doi:10.1038/leu.2009.141 · Cited by 331
Abdel-Wahab, O., Manshouri, T., Patel, J., Harris, K., Yao, J., Hedvat, C., Heguy, A., Bueso-Ramos, C., Kantarjian, H., Levine, R. L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3783 · Cited by 326
Self-citationTefferi, A., Lasho, T. L., Abdel-Wahab, O., Guglielmelli, P., Patel, J., Caramazza, D., Pieri, L., Finke, C. M., Kilpivaara, O., Wadleigh, M., et al. (2010) · Leukemia · doi:10.1038/leu.2010.113 · Cited by 318
Self-citationGondek, L. P., Tiu, R., O'Keefe, C. L., Sekeres, M. A., Theil, K. S., & Maciejewski, J. P. (2008) · Blood · doi:10.1182/blood-2007-05-092304 · Cited by 315
Christiansen, D. H., Andersen, M. K., & Pedersen-Bjergaard, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1405 · Cited by 308
Dunbar, A. J., Gondek, L. P., O'Keefe, C. L., Makishima, H., Rataul, M. S., Szpurka, H., Sekeres, M. A., Wang, X. F., McDevitt, M. A., & Maciejewski, J. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2754 · Cited by 299
Mutations in CBL occur frequently in juvenile myelomonocytic leukemia
Loh, M. L., Sakai, D. S., Flotho, C., Kang, M., Fliegauf, M., Archambeault, S., Mullighan, C. G., Chen, L., Bergstraesser, E., Bueso-Ramos, C. E., et al. (2009) · Blood · doi:10.1182/blood-2009-01-198416 · Cited by 286
Harada, H., Harada, Y., Niimi, H., Kyo, T., Kimura, A., & Inaba, T. (2004) · Blood · doi:10.1182/blood-2003-09-3074 · Cited by 281
Sloand, E. M., Wu, C. O., Greenberg, P., Young, N., & Barrett, J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.9214 · Cited by 277
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)
Kosmider, O., Gelsi-Boyer, V., Cheok, M., Grabar, S., Della-Valle, V., Picard, F., Viguié, F., Quesnel, B., Beyne-Rauzy, O., Solary, E., et al. (2009) · Blood · doi:10.1182/blood-2009-04-215814 · Cited by 276
Boultwood, J., Perry, J., Pellagatti, A., Fernandez-Mercado, M., Fernandez-Santamaria, C., Calasanz, M. J., Larrayoz, M. J., Garcia-Delgado, M., Giagounidis, A., Malcovati, L., et al. (2010) · Leukemia · doi:10.1038/leu.2010.20 · Cited by 264
Narrowing and genomic annotation of the commonly deleted region of the 5q− syndrome
Boultwood, J., Fidler, C., Strickson, A. J., Watkins, F., Gama, S., Kearney, L., Tosi, S., Kasprzyk, A., Cheng, J.-F., Jaju, R. J., et al. (2002) · Blood · doi:10.1182/blood.v99.12.4638 · Cited by 264
Gröschel, S., Lugthart, S., Schlenk, R. F., Valk, P. J. M., Eiwen, K., Goudswaard, C., van Putten, W. J. L., Kayser, S., Verdonck, L. F., Lübbert, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.0646 · Cited by 256
Kosmider, O., Gelsi-Boyer, V, Slama, L., Dreyfus, F., Beyne-Rauzy, O., Quesnel, B., Hunault-Berger, M., Slama, B., Vey, N., Lacombe, C., et al. (2010) · Leukemia · doi:10.1038/leu.2010.52 · Cited by 247
TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia
Kosmider, O., Gelsi-Boyer, V., Ciudad, M., Racoeur, C., Jooste, V., Vey, N., Quesnel, B., Fenaux, P., Bastie, J.-N., Beyne-Rauzy, O., et al. (2009) · Haematologica · doi:10.3324/haematol.2009.011205 · Cited by 247
Genetics of therapy-related myelodysplasia and acute myeloid leukemia
Pedersen-Bjergaard, J., Andersen, M. K., Andersen, M. T., & Christiansen, D. H. (2008) · Leukemia · doi:10.1038/sj.leu.2405078 · Cited by 232
Beau, M. M. L., Espinosa, R., Davis, E. M., Eisenbart, J. D., Larson, R. A., & Green, E. D. (1996) · PubMed · doi:10.1182/blood.v88.6.1930.bloodjournal8861930 · Cited by 232
Smith, A. E., Mohamedali, A. M., Kulasekararaj, A., Lim, Z., Gäken, J., Lea, N. C., Przychodzen, B., Mian, S. A., Nasser, E. E., Shooter, C., et al. (2010) · Blood · doi:10.1182/blood-2010-03-274704 · Cited by 224
Flt3-dependent transformation by inactivating c-Cbl mutations in AML
Sargin, B., Choudhary, C., Crosetto, N., Schmidt, M. H. H., Grundler, R., Rensinghoff, M., Thiessen, C., Tickenbrock, L., Schwäble, J., Brandts, C., et al. (2007) · Blood · doi:10.1182/blood-2007-01-066076 · Cited by 213
Joslin, J. M., Fernald, A. A., Tennant, T. R., Davis, E. M., Kogan, S. C., Anastasi, J., Crispino, J. D., & Le Beau, M. M. (2007) · Blood · doi:10.1182/blood-2007-01-068809 · Cited by 210
Szpurka, H., Tiu, R., Murugesan, G., Aboudola, S., Hsi, E. D., Theil, K. S., Sekeres, M. A., & Maciejewski, J. P. (2006) · Blood · doi:10.1182/blood-2006-02-005751 · Cited by 209
Liu, T. X., Becker, M. W., Jelinek, J., Wu, W.-S., Deng, M., Mikhalkevich, N., Hsu, K., Bloomfield, C. D., Stone, R. M., DeAngelo, D. J., et al. (2007) · Nature Medicine · doi:10.1038/nm1512 · Cited by 207
Paquette, R., Landaw, E., Pierre, R., Kahan, J., Lubbert, M., Lazcano, O., Isaac, G., McCormick, F., & Koeffler, H. (1993) · Blood · doi:10.1182/blood.v82.2.590.590 · Cited by 194
Wei, S., Chen, X., Rocha, K., Epling-Burnette, P. K., Djeu, J. Y., Liu, Q., Byrd, J., Sokol, L., Lawrence, N., Pireddu, R., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811267106 · Cited by 192
Thol, F., Weissinger, E. M., Krauter, J., Wagner, K., Damm, F., Wichmann, M., Gohring, G., Schumann, C., Bug, G., Ottmann, O., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.025494 · Cited by 191
Du, Y., Jenkins, N. A., & Copeland, N. G. (2005) · Blood · doi:10.1182/blood-2005-03-1113 · Cited by 189
EVI1 induces myelodysplastic syndrome in mice
Buonamici, S., Li, D., Chi, Y., Zhao, R., Wang, X., Brace, L., Ni, H., Saunthararajah, Y., & Nucifora, G. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21716 · Cited by 181
Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies
Makishima, H., Jankowska, A. M., Tiu, R. V., Szpurka, H., Sugimoto, Y., Hu, Z., Saunthararajah, Y., Guinta, K., Keddache, M. A., Putnam, P., et al. (2010) · Leukemia · doi:10.1038/leu.2010.167 · Cited by 179
Fisher, C. L., Pineault, N., Brookes, C., Helgason, C. D., Ohta, H., Bodner, C., Hess, J. L., Humphries, R. K., & Brock, H. W. (2009) · Blood · doi:10.1182/blood-2009-07-230698 · Cited by 174
Preudhomme, C., Renneville, A., Bourdon, V., Philippe, N., Roche-Lestienne, C., Boissel, N., Dhedin, N., André, J.-M., Cornillet-Lefebvre, P., Baruchel, A., et al. (2009) · Blood · doi:10.1182/blood-2008-07-168260 · Cited by 173
Bench, A. J., Nacheva, E. P., Hood, T. L., Holden, J. L., French, L., Swanton, S., Champion, K. M., Li, J., Whittaker, P., Stavrides, G., et al. (2000) · Oncogene · doi:10.1038/sj.onc.1203728 · Cited by 165
Cho, Y.-S., Kim, E., Park, U., Sin, H., & Um, S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512616200 · Cited by 165
Clinical significance of Y chromosome loss in hematologic disease
Wiktor, A., Rybicki, B. A., Piao, Z. S., Shurafa, M., Barthel, B., Maeda, K., & Van Dyke, D. L. (2000) · Genes, Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(200001)27:1<11::aid-gcc2>3.0.co;2-i · Cited by 165
Bacher, U., Haferlach, T., Kern, W., Haferlach, C., & Schnittger, S. (2007) · Haematologica · doi:10.3324/haematol.10869 · Cited by 164
Establishment of a Normal Hematopoietic and Leukemia Stem Cell Hierarchy
Chao, M. P., Seita, J., & Weissman, I. L. (2008) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2008.73.031 · Cited by 163
AML1 mutations induced MDS and MDS/AML in a mouse BMT model
Watanabe‐Okochi, N., Kitaura, J., Ono, R., Harada, H., Harada, Y., Komeno, Y., Nakajima, H., Nosaka, T., Inaba, T., & Kitamura, T. (2008) · Blood · doi:10.1182/blood-2007-01-068346 · Cited by 160
Schaub, F. X., Looser, R., Li, S., Hao-Shen, H., Lehmann, T., Tichelli, A., & Skoda, R. C. (2010) · Blood · doi:10.1182/blood-2009-09-245381 · Cited by 157
Pedersen-Bjergaard, J., Christiansen, D. H., Desta, F. Z., & Andersen, M. K. (2006) · Leukemia · doi:10.1038/sj.leu.2404381 · Cited by 155
Lim, Z. Y., Killick, S. B., Germing, U., Cavenagh, J. D., Culligan, D. J., Bacigalupo, A. P., Marsh, J. C. W., & Mufti, G. J. (2007) · Leukemia · doi:10.1038/sj.leu.2404747 · Cited by 154
Chen, C., Lin, L., Tang, J., Ko, B.-S., Tsay, W., Chou, W., Yao, M., Wu, S., Tseng, M., & Tien, H. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06811.x · Cited by 152
López‐Villar, O., García, J. L., Sanchez-Guijo, F. M., Robledo, C., Villarón, E. M., Hernández‐Campo, P. M., López-Holgado, N., Díez‐Campelo, M., Barbado, M. V., Pérez‐Simón, J. A., et al. (2009) · Leukemia · doi:10.1038/leu.2008.361 · Cited by 145
Malcovati, L., Porta, M. G. D., Pietra, D., Boveri, E., Pellagatti, A., Gallì, A., Travaglino, E., Brisci, A., Rumi, E., Passamonti, F., et al. (2009) · Blood · doi:10.1182/blood-2009-05-222331 · Cited by 144
Tsimberidou, A. M., Estey, E. H., Wen, S., Pierce, S. A., Kantarjian, H. M., Albitar, M. X., & Kurzrock, R. (2008) · Cancer · doi:10.1002/cncr.23785 · Cited by 136
Reindl, C., Quentmeier, H., Petropoulos, K., Greif, P. A., Benthaus, T., Argiropoulos, B., Mellert, G., Vempati, S., Duyster, J., Buske, C., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1325 · Cited by 136
Opposing roles of polycomb repressive complexes in hematopoietic stem and progenitor cells
Majewski, I. J., Ritchie, M. E., Phipson, B., Corbin, J., Pakusch, M., Ebert, A., Busslinger, M., Koseki, H., Hu, Y., Smyth, G. K., et al. (2010) · Blood · doi:10.1182/blood-2009-12-260760 · Cited by 135
Christiansen, D. H., Andersen, M. K., & Pedersen-Bjergaard, J. (2004) · Blood · doi:10.1182/blood-2004-02-0754 · Cited by 135
Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias
Carbuccia, N., Trouplin, V., Gelsi‐Boyer, V., Murati, A., Rocquain, J., Adélaïde, J., Olschwang, S., Xerri, L., Vey, N., Chaffanet, M., et al. (2009) · Leukemia · doi:10.1038/leu.2009.218 · Cited by 134
Christiansen, D. H., Andersen, M. K., Desta, F. Z., & Pedersen-Bjergaard, J. (2005) · Leukemia · doi:10.1038/sj.leu.2404009 · Cited by 132
Disease mutations in RUNX1 and RUNX2 create nonfunctional, dominant‐negative, or hypomorphic alleles
Matheny, C., Speck, M. E., Cushing, P. R., Zhou, Y., Corpora, T., Regan, M. C., Newman, M. N., Roudaia, L., Speck, C. L., Gu, T.-L., et al. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601568 · Cited by 131
The E3 ubiquitin ligase c-Cbl restricts development and functions of hematopoietic stem cells
Rathinam, C., Thien, C. B. F., Langdon, W. Y., Gu, H., & Flavell, R. A. (2008) · Genes & Development · doi:10.1101/gad.1651408 · Cited by 127
Epigenetic Changes in the Myelodysplastic Syndrome
Issa, J. J. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.02.007 · Cited by 119
Ho, C. Y., Otterud, B., Legare, R. D., Varvil, T., Saxena, R., Dehart, D. B., Kohler, S., Aster, J. C., Dowton, S. B., Li, F., et al. (1996) · Blood · doi:10.1182/blood.v87.12.5218.bloodjournal87125218 · Cited by 115
Clinical significance of Y chromosome loss in hematologic disease
Wiktor, A. E., Rybicki, B. A., Piao, Z. S., Shurafa, M. S., Barthel, B. G., Maeda, K., & Dyke, D. L. V. (2000) · Genes Chromosomes and Cancer · Cited by 115
The Apcmin mouse has altered hematopoietic stem cell function and provides a model for MPD/MDS
Lane, S., Sykes, S. M., Al‐Shahrour, F., Shterental, S., Paktinat, M., Celso, C. L., Jesneck, J. L., Ebert, B. L., Williams, D. A., & Gilliland, D. G. (2010) · Blood · doi:10.1182/blood-2009-11-251728 · Cited by 114
Self-citationJädersten, M., Saft, L., Pellagatti, A., Göhring, G., Wainscoat, J. S., Boultwood, J., Porwit‐MacDonald, A., Schlegelberger, B., & Hellström‐Lindberg, E. (2009) · Haematologica · doi:10.3324/haematol.2009.011528 · Cited by 113
Horrigan, S. K., Arbieva, Z. H., Xie, H. Y., Kravarusic, J., Fulton, N. C., Naik, H. B., Le, T. T., & Westbrook, C. A. (2000) · Blood · doi:10.1182/blood.v95.7.2372 · Cited by 111
Fisher, C. L., Randazzo, F. M., Humphries, R. K., & Brock, H. W. (2006) · Gene · doi:10.1016/j.gene.2005.10.033 · Cited by 104
Heinrichs, S., Kulkarni, R. V., Bueso‐Ramos, C. E., Levine, R. L., Loh, M. L., Li, C., Neuberg, D. S., Kornblau, S. M., Issa, J. J., Gilliland, D. G., et al. (2009) · Leukemia · doi:10.1038/leu.2009.82 · Cited by 102
Self-citationKaneko, H., Misawa, S., Horiike, S., Nakai, H., & Kashima, K. (1995) · Blood · doi:10.1182/blood.v85.8.2189.bloodjournal8582189 · Cited by 100
The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator
Soderholm, J., Kobayashi, H., Mathieu, C., Rowley, J., & Nucifora, G. (1997) · Leukemia · doi:10.1038/sj.leu.2400584 · Cited by 100
Ubiquitination and degradation of the thrombopoietin receptor c-Mpl
Saur, S. J., Sangkhae, V., Geddis, A. E., Kaushansky, K., & Hitchcock, I. S. (2009) · Blood · doi:10.1182/blood-2009-06-227033 · Cited by 98
Döhner, K., Hehmann, U., Brown, J. M., Hetzel, C., Stewart, J., Lowther, G. W., Scholl, C., Fröhling, S., Cuneo, A., Tsui, L. ‐., et al. (2001) · Hämatologie und Bluttransfusion · doi:10.1007/978-3-642-18156-6_3 · Cited by 94
Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations
Harada, Y., & Harada, H. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21769 · Cited by 94
Kita‐Sasai, Y., Horiike, S., Misawa, S., Kaneko, H., Kobayashi, M., Nakao, M., Nakagawa, H., Fujii, H., & Taniwaki, M. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03073.x · Cited by 88
Döhner, K., Brown, J. M., Hehmann, U., Hetzel, C., Stewart, J., Lowther, G. W., Scholl, C., Fröhling, S., Cuneo, A., Tsui, L., et al. (1998) · Blood · doi:10.1182/blood.v92.11.4031 · Cited by 87
EVI1 Impairs Myelopoiesis by Deregulation of PU.1 Function
Laricchia‐Robbio, L., Premanand, K., Rinaldi, C. R., & Nucifora, G. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2562 · Cited by 81
Haploinsufficiency of Apc leads to ineffective hematopoiesis
Wang, J., Fernald, A. A., Anastasi, J., Beau, M. M. L., & Qian, Z. (2010) · Blood · doi:10.1182/blood-2009-11-251835 · Cited by 79
Wong, A. K., Fang, B., Zhang, L., Guo, X., Lee, S. B., & Schreck, R. R. (2008) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2008-132-1329-lotyca · Cited by 78
Laricchia‐Robbio, L., Fazzina, R., Li, D., Rinaldi, C. R., Sinha, K. K., Chakraborty, S., & Nucifora, G. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00363-06 · Cited by 78
Repression of RUNX1 Activity by EVI1: A New Role of EVI1 in Leukemogenesis
Senyuk, V. I., Sinha, K. K., Li, D., Rinaldi, C. R., Yanamandra, S., & Nucifora, G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3962 · Cited by 74
Abbas, S., Rotmans, G., Löwenberg, B., & Valk, P. J. M. (2008) · Haematologica · doi:10.3324/haematol.13187 · Cited by 74
TET2 mutations in myelodysplasia and myeloid malignancies
Mullighan, C. G. (2009) · Nature Genetics · doi:10.1038/ng0709-766 · Cited by 73
Look, A. T. (2005) · Hematology · doi:10.1182/asheducation-2005.1.156 · Cited by 72
Niimi, H., Harada, H., Harada, Y., Ding, Y., Imagawa, J., Inaba, T., Kyo, T., & Kimura, A. (2006) · Leukemia · doi:10.1038/sj.leu.2404136 · Cited by 69
The Genetic Basis of Myeloproliferative Disorders
Skoda, R. C. (2007) · Hematology · doi:10.1182/asheducation-2007.1.1 · Cited by 68
Nimer, S. D. (2008) · Hematology · doi:10.1182/asheducation-2008.1.43 · Cited by 68
Loh, M. L., Martinelli, S., Cordeddu, V., Reynolds, M. G., Vattikuti, S., Lee, C. M., Wulfert, M., Germing, U., Haas, P. S., Niemeyer, C. M., et al. (2004) · Leukemia Research · doi:10.1016/j.leukres.2004.10.001 · Cited by 65
Steensma, D. P., Gibbons, R. J., Mesa, R. A., Tefferi, A., & Higgs, D. R. (2004) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2004.00363.x · Cited by 63
Configuration of the TP53 Gene as an Independent Prognostic Parameter of Myelodysplastic Syndrome
Horiike, S., Kita‐Sasai, Y., Nakao, M., & Taniwaki, M. (2003) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/1042819031000067620 · Cited by 51
Graubert, T. A., Payton, M. A., Shao, J., Walgren, R. A., Monahan, R. S., Frater, J. L., Walshauser, M. A., Martin, M. G., Kasai, Y., & Walter, M. J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004583 · Cited by 50
Ye, Y., McDevitt, M. A., Guo, M., Zhang, W., Galm, O., Gore, S. D., Karp, J. E., Maciejewski, J. P., Kowalski, J., Tsai, H., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1153 · Cited by 49
Definitive hematopoiesis requires Runx1 C-terminal-mediated subnuclear targeting and transactivation
Dowdy, C. R., Xie, R., Frederick, D., Hussain, S., Zaidi, S. K., Vradii, D., Javed, A., Li, X., Jones, S. N., Lian, J. B., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp568 · Cited by 49
Gondek, L. P., Haddad, A. S., O’Keefe, C. L., Tiu, R. V., Włodarski, M. W., Sekeres, M. A., Theil, K. S., & Maciejewski, J. P. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2007.08.009 · Cited by 48
Wardrop, D., & Steensma, D. P. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07526.x · Cited by 44
Significant increase of self-renewal in hematopoietic cells after forced expression of EVI1
Laricchia‐Robbio, L., & Nucifora, G. (2007) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2007.07.012 · Cited by 40
Pitchford, C. W., Hettinga, A. C., & Reichard, K. K. (2010) · American Journal of Clinical Pathology · doi:10.1309/ajcpz4jl5zmrpftd · Cited by 40
The Genetic Basis of Myelodysplastic Syndromes
Bejar, R. L., & Ebert, B. L. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.02.001 · Cited by 29
Self-citationWong, J. C. Y., Zhang, Y., Lieuw, K. H., Tran, M. T., Forgó, E., Weinfurtner, K. M., Alzamora, P., Kogan, S. C., Akagi, K., Wolff, L., et al. (2010) · Blood · doi:10.1182/blood-2009-07-232504 · Cited by 26
Lenalidomide for Treatment of Myelodysplastic Syndromes: Current Status and Future Directions
Komrokji, R. S., & List, A. F. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.02.013 · Cited by 24
Codon 12 ras mutations in patients with myelodysplastic syndrome: incidence and prognostic value
Constantinidou, M., Chalevelakis, G., Economopoulos, T., Koffa, M. D., Liloglou, T., Anastassiou, C., Yalouris, A., Spandidos, D. A., & Raptis, S. A. (1997) · Annals of Hematology · doi:10.1007/s002770050248 · Cited by 23
Kumar, M., Narla, A., Nonami, A., Ball, B. J., Chin, C., Chen, C. S., Kutok, J. L., Galili, N., Raza, A., Attar, E. C., et al. (2009) · Blood · doi:10.1182/blood.v114.22.947.947 · Cited by 17
Self-citationCytogenetic Risk Features in MDS-Update and Present State.
Schanz, J., Tuechler, H., Solé, F. G., Mallo, M., Hildebrandt, B., Slovak, M. L., Ohyashiki, K., Steidl, C., Fonatsch, C., Pfeilstöecker, M., et al. (2009) · Blood · doi:10.1182/blood.v114.22.2772.2772 · Cited by 11
Cited by
Frequent pathway mutations of splicing machinery in myelodysplasia
Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., et al. (2011) · Nature · doi:10.1038/nature10496 · Cited by 2,029
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-Manero, G., Kantarjian, H., Raza, A., Levine, R. L., Neuberg, D., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013343 · Cited by 1,627
Self-citationLandscape of genetic lesions in 944 patients with myelodysplastic syndromes
Haferlach, T., Nagata, Y., Grossmann, V, Okuno, Y., Bacher, U., Nagae, G., Schnittger, S., Sanada, M., Kon, A., Alpermann, T., et al. (2014) · Leukemia · doi:10.1038/leu.2013.336 · Cited by 1,532
TETonic shift: biological roles of TET proteins in DNA demethylation and transcription
Pastor, W. A., Aravind, L., & Rao, A. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3589 · Cited by 897
Detectable clonal mosaicism from birth to old age and its relationship to cancer
Laurie, C. C., Laurie, C. A., Rice, K., Doheny, K. F., Zelnick, L. R., McHugh, C. P., Ling, H., Hetrick, K. N., Pugh, E. W., Amos, C., et al. (2012) · Nature Genetics · doi:10.1038/ng.2271 · Cited by 594
Metadata
- Authors
- Bejar, R., Levine, R., & Ebert, B. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-02-10
- Volume
- 29
- Issue
- 5
- Pages
- 504-515
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2076367236
- Cited by
- 305
- References
- 134
- FWCI
- 27.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.